Strategies for MMP inhibition in cancer: innovations for the post-trial era

By Christopher M. Overall, C. López‐Otín. Nature Reviews. Cancer, 2002

1,357 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0f5ed5c5a62ca2fd9025e7c2a237c9716d192cf2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Francis G. Spinale
2. P. E. Van den Steen
3. J. Vandooren
4. G. Opdenakker
5. M. Luisa Iruela-Arispe
6. Sunyoung Lee
7. Soo-Hyun Kim
8. J. Turnbull

In Molecular Biology

1. Francis G. Spinale
2. M. Luisa Iruela-Arispe
3. Chunhong Yan
4. D. Boyd
5. Sunyoung Lee
6. Soo-Hyun Kim
7. J. Turnbull
8. S. Guimond

In Oncology

1. Francis G. Spinale
2. M. Luisa Iruela-Arispe
3. Soo-Hyun Kim
4. J. Turnbull
5. S. Guimond
6. B. Turk
7. C. Malemud
8. J. Vandooren

Citations in the corpus

• Targeting proteases: successes, failures and future prospects (2006, background): “Musculoskeletal side effects observed could be at least partially attributed to the crossreactivity of the inhibitors, as well as to poor understanding of their complex biology, which is still an issu”
• Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade (2013, background): “For example, it was found that tumor-surrounding stromal cells often are major producers of tumor-associated proteases (Overall & Lopez-Otin, 2002; Stuelten et al., 2005).”
• Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors (2005, background): “Recent findings that the inactivation of some MMPs by homologous recombination facilitates tumor expansion has propelled a reinterpretation of the initial protumorigenic view of MMPs in cancer (Overall and Lopez-Otin, 2002; Balbin et al., 2003).”
• Matrix metalloproteinases (MMPs) in health and disease: an overview. (2006, background): “Biochemistry 32(16), 4286-4292 (1993) 15.”
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases (2007, background): “However, during clinical trials of metastatic cancer, severe side effects were observed, thus leading researchers to reappraise the use of MMPIs for the therapy of invasive cance”
• Regulation of matrix metalloproteinase gene expression (2007, background): “…15 September 2006; Accepted 18 October 2006 DOI: 10.1002/jcp.20948 The members of matrix metalloproteinase (MMP) family, currently 24 (Overall and Lopez-Otin, 2002), share a catalytic domain coordinated by zinc, catalyzing the degradation of protein components of extracellular matrix…”